Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

Obesity Surgery

Volumn 22, Issue 7, 2012, Pages 1084-1096

  Jacobsen, S H ^a   Olesen, S C ^a   Dirksen, C ^a   Jorgensen N B ^a   Bojsen Moller K N ^a   Kielgast, U ^a   Worm, D ^a   Almdal, T ^a   Naver, L S ^a   Hvolris, L E ^a   Rehfeld, J F ^a   Wulff, B S ^c   Clausen, T R ^c   Hansen, D L ^a   Holst, J J ^b   Madsbad, S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Appetite regulating hormone; Gastric bypass; Gastrointestinal hormones; Incretins; Insulin resistance; Obesity

Indexed keywords

AMYLIN; C PEPTIDE; CHOLECYSTOKININ; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; LEPTIN; PANCREAS POLYPEPTIDE; PEPTIDE YY [3-36]; SOMATOSTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DECREASED APPETITE; DIET RESTRICTION; FATTY ACID ANALYSIS; FEMALE; FOOD INTAKE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POSTGASTRECTOMY SYNDROME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH BYPASS;

ADULT; APPETITE; C-PEPTIDE; CHOLECYSTOKININ; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GASTRINS; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; LEPTIN; MALE; MIDDLE AGED; OBESITY, MORBID; PANCREATIC POLYPEPTIDE; PEPTIDE YY; POSTPRANDIAL PERIOD; SOMATOSTATIN; TIME FACTORS; WEIGHT LOSS;

EID: 84862604197     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0621-4     Document Type: Article

References (73)

1. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med. 2009;122:248-56.
2. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-50.
3. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-30.
4. Korner J, Bessler M, Inabnet W, et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3:597-601.
5. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14.
6. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-84.
7. Beckman LM, Beckman TR, Sibley SD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. JPEN J Parenter Enteral Nutr. 2011;35:169-80.
8. Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14:15-23.
9. Falken Y, Hellstrom PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227-35.
10. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care. 2010;33:1438-42.
11. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780-5.
12. Umeda LM, Silva EA, Carneiro G, et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21(7):896-901.
13. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706-13.
14. Herrmann C, Goke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56:117-26.
15. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138:159-66.
16. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-39.
17. Rijkelijkhuizen JM, McQuarrie K, Girman CJ, et al. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism. 2010;59:502-11.
18. Carr RD, Larsen MO, Winzell MS, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab. 2008;295:E779-84.
19. Lindgren O, Carr R, Holst J, et al. Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. Diabetes Obes Metab. 2011;13(9):863-5.
20. Deitel M. The change in the dumping syndrome concept. Obes Surg. 2008;18:1622-4.
21. Tack J, Arts J, Caenepeel P, et al. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol. 2009;6:583-90.
22. Tokunaga M, Hiki N, Ohyama S, et al. Effects of reconstruction methods on a patient's quality of life after a proximal gastrectomy: subjective symptoms evaluation using questionnaire survey. Langenbecks Arch Surg. 2009;394:637-41.
23. Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535-9.
24. Wilken M, Larsen FS, Buckley D, et al. New highly specific immunoassays for glucagon-like peptide 1 (GLP-1). Diabetologia. 1999;42(1):A196.
25. Krarup T, Madsbad S, Moody AJ, et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab. 1983;56:1306-12.
26. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept. 1984;9:35-46.
27. Orskov C, Jeppesen J, Madsbad S, et al. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991;87:415-23.
28. Hartmann B, Johnsen AH, Orskov C, et al. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21:73-80.
29. Hilsted L, Holst JJ. On the accuracy of radioimmunological determination of somatostatin in plasma. Regul Pept. 1982;4:13-31.
30. Rehfeld JF, Stadil F, Rubin B. Production and evaluation of antibodies for the radioimmunoassay of gastrin. Scand J Clin Lab Invest. 1972;30:221-32.
31. Rehfeld JF. Gastrins in serum. A review of gastrin radioimmunoanalysis and the discovery of gastrin heterogeneity in serum. Scand J Gastroenterol. 1973;8:577-83.
32. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem. 1998;44:991-1001.
33. Rehfeld JF, Sun G, Christensen T, et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab. 2001;86:251-8.
34. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210-5.
35. Lin E, Phillips LS, Ziegler TR, et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007;56:735-42.
36. Turner RC, Holman RR. Insulin rather than glucose homoeostasis in the pathophysiology of diabetes. Lancet. 1976;1:1272-4.
37. Camastra S, Gastaldelli A, Mari A et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54(8):2093-102.
38. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985;61:917-25.
39. Czupryniak L, Pawlowski M, Szymanski D, et al. Plasma glucose after stomach or jejunum glucose infusion in Roux-en-Y gastric bypass patients - a possible implication for early satiety mechanism. Exp Clin Endocrinol Diabetes. 2011;119:186-9.
40. Rodieux F, Giusti V, D'Alessio DA, et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring). 2008;16:298-305.
41. Dirksen C, Hansen DL, Madsbad S et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care. 2010;33(2):375-7
42. Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond). 2010;34:462-71.
43. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709-16.
44. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608-15.
45. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735-40.
46. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf). 2011;201:405-11.
47. Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-85.
48. Laferrere B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95:4072-6.
49. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1449-54.
50. Nishizawa M, Nakabayashi H, Uchida K, et al. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst. 1996;61:149-54.
51. Schwartz TW, Rehfeld JF, Stadil F, et al. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet. 1976;1:1102-5.
52. Bloom SR, Polak JM. Gut hormones. Adv Clin Chem. 1980;21:177-244.
53. Holst JJ. Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like Peptide 1. Diabetes. 2011;60:2203-5.
54. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-8.
55. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854-9.
56. Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571-84.
57. de Heer J, Pedersen J, Orskov C. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia. 2007;50:2135-42.
58. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44-54.
59. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083-6.
60. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89:71-84.
61. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 2005;90:359-65.
62. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring). 2006;14:1553-61.
63. Morinigo R, Vidal J, Lacy AM, et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 2008;247:270-5.
64. Martins C, Kjelstrup L, Mostad IL, et al. Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on ghrelin, obestatin, and ghrelin/obestatin ratio in morbidly obese patients. Obes Surg. 2011;21:751-8.
65. Sundbom M, Holdstock C, Engstrom BE, et al. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg. 2007;17:304-10.
66. Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition. 2000;16:858-65.
67. Tadross JA, le Roux CW. The mechanisms of weight loss after bariatric surgery. Int J Obes (Lond). 2009;33 Suppl 1:S28-32.
68. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763-70.
69. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-42.
70. Schrumpf E, Giercksky KE, Nygaard K, et al. Gastrin secretion before and after gastric bypass surgery for morbid obesity. Scand J Gastroenterol. 1981;16:721-5.
71. Schrumpf E, Bergan A, Djoseland O, et al. The effect of gastric bypass operation on glucose tolerance in obesity. Scand J Gastroenterol Suppl. 1985;107:24-31.
72. Padoin AV, Galvao NM, Moretto M, et al. Obese patients with type 2 diabetes submitted to banded gastric bypass: greater incidence of dumping syndrome. Obes Surg. 2009;19:1481-4.
73. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care. 1999;2:69-78.